Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Nanostr.technol.

Start price
Target price
Perf. (%)
€57.50
13.12.20
-
13.12.21
-41.91%
14.12.21

Risky Investment
buy
Ebix Inc.

Start price
Target price
Perf. (%)
€30.20
13.12.20
€35.00
13.12.21
-12.98%
14.12.21

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
SLM Solutions Group AG

Start price
Target price
Perf. (%)
€15.50
13.12.20
-
13.12.21
5.42%
14.12.21

overvalued
Revenue decline/stagnation expected
EBIT decline/stagnation expected
Voltabox

Start price
Target price
Perf. (%)
€3.80
13.12.20
-
13.12.21
-55.21%
14.12.21

Probably not worthwhile Investment
Bad rating
High risks for its business
Growths much slower than the competition
Curis Inc.

Start price
Target price
Perf. (%)
€6.35
13.12.20
-
13.12.21
37.01%
16.02.21

Below average Marketposition
Probably not worthwhile Investment
Significant cyclical dependencies
Little known brand
Lexicon Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€2.66
13.12.20
-
13.12.21
143.95%
16.02.21

Probably not worthwhile Investment
Significant cyclical dependencies
Verrica Pharmaceuticals

Start price
Target price
Perf. (%)
€8.75
12.12.20
-
12.12.21
-2.29%
13.12.21

Probably not worthwhile Investment
Inseego Corp.

Start price
Target price
Perf. (%)
€12.26
12.12.20
-
12.12.21
-54.63%
13.12.21

Probably not worthwhile Investment
PhaseBio Pharmaceuticals Inc

Start price
Target price
Perf. (%)
€3.60
12.12.20
-
12.12.21
-42.22%
13.12.21

Probably not worthwhile Investment
buy
Harmony Gold Mining

Start price
Target price
Perf. (%)
€3.42
12.12.20
€8.50
12.12.21
2.92%
22.11.21

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Very low/no dividend yield expected
buy
Formycon AG

Start price
Target price
Perf. (%)
€65.20
12.12.20
-
12.12.21
-7.06%
11.03.21

Could be worthwhile Investment >10% per year
Overstock.com

Start price
Target price
Perf. (%)
€45.56
12.12.20
-
12.12.21
74.51%
08.02.21

Stable Large shareholder and/or long term investor
EBIT decline/stagnation expected
Few uniques
Sustainability is little important
buy
Bluestone Resources Inc.

Start price
Target price
Perf. (%)
€1.27
11.12.20
€2.00
11.12.21
4.25%
12.12.21

Could be very worthwhile Investment >20% year
SPI Energy Co Ltd ADR

Start price
Target price
Perf. (%)
€6.65
10.12.20
€6.00
10.12.21
0.00%
22.12.20

Valuable balance sheet
Capable Management
Sustainability is not important
ROE lower than 10% per year
Inovio Pharma

Start price
Target price
Perf. (%)
€9.35
10.12.20
€7.00
10.12.21
20.86%
20.02.21

Very low/no dividend yield expected
Risky balance sheet
ROE lower than 10% per year
Increased challenges to pay loans and raise capital
2G Energy AG

Start price
Target price
Perf. (%)
€84.40
10.12.20
€75.00
10.12.21
-0.71%
22.12.20

Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Higher EBIT margin than peer group
Curis Inc.

Start price
Target price
Perf. (%)
€5.90
09.12.20
€4.00
7.63%
14.12.20

Risky Investment
buy
Sii

Start price
Target price
Perf. (%)
€24.20
09.12.20
-
09.12.21
83.06%
10.12.21

Could be worthwhile Investment >10% per year
buy
Nissan Motor Co Ltd

Start price
Target price
Perf. (%)
€4.50
09.12.20
€5.00
2.24%
16.12.20

buy
Arcimoto Inc

Start price
Target price
Perf. (%)
€11.50
08.12.20
€28.00
08.12.21
-43.13%
25.05.21

Lexicon Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€2.56
08.12.20
-
6.64%
10.12.20

Risky Investment
buy
Amadeus FiRe AG

Start price
Target price
Perf. (%)
€121.80
07.12.20
€168.00
07.12.21
49.10%
08.12.21

Could be worthwhile Investment >10% per year
buy
Jenoptik AG

Start price
Target price
Perf. (%)
€25.42
07.12.20
€31.00
07.12.21
45.16%
08.12.21

buy
Biocryst Pharmaceuticals

Start price
Target price
Perf. (%)
€5.51
07.12.20
€25.00
07.12.21
93.92%
08.12.21

Could be very worthwhile Investment >20% year
Nel ASA

Start price
Target price
Perf. (%)
€2.19
06.12.20
€1.00
2.51%
08.12.20

Future proof or reliable business model
Innovative
Valuable balance sheet
ROE higher than 10% per year